|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine, for the first time, the frequency of slow acetylators in Moroccan population by genotyping of NAT2 gene variants and determining the genotype c1/c1 for CYP2E1 gene, in order to predict adverse effects of Tuberculosis treatment, particularly hepatotoxicity.
|
25544508 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
|
23150149 |
2013 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens.
|
24888881 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
|
24383060 |
2013 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
|
20392357 |
2010 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We could not demonstrate an increased risk of ATDH related to the presence of slow NAT2 polymorphisms among this Caucasian TB cohort.
|
22283902 |
2011 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.
|
18023090 |
2007 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that NAT2*13A and NAT2*6B variant alleles are risk factors for developing hepatotoxicity, and PLWHA with genotypes NAT2*13A/NAT2*13A and NAT2*13A/NAT2*6B should be targeted for specific care to reduce the risk of hepatotoxicity during treatment for tuberculosis.
|
31734174 |
2020 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
|
31066138 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis.
|
24533708 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
|
22947533 |
2013 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that various NAT2 genotypes in Chinese tuberculosis patients have great impact on the metabolism capacity of NAT2.
|
16182272 |
2006 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of anti-TB DIH was significantly higher in slow acetylator (SA) than in intermediate and rapid acetylator of NAT2 genotypes (odds ratio: 2.3, P = 0.01).
|
23875638 |
2013 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings may be explained, in part, by changes in the metabolism of the anti-TB drug isoniazid induced via NAT2 and CYP2E1, a metabolic process known to produce hepatotoxic intermediates.
|
22506592 |
2012 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of NAT2 genotypes with plasma isoniazid concentrations was determined by measuring the plasma levels in tuberculosis patients at different time points using reverse-phase high-performance liquid chromatography (HPLC).
|
19351215 |
2009 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study demonstrated no association between NAT2 genotype and DIH in the north Indian patients with tuberculosis.
|
28474630 |
2016 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection.
|
21558457 |
2012 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adult patients with TB treated in the Revised National TB Control Programme (RNTCP) in Chennai, Tamil Nadu, were genotyped for NAT2 gene polymorphism, and two-hour post-dosing INH concentrations were compared between the different genotypes.
|
28574024 |
2017 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the high proportion of NAT2 "fast" alleles may partially explain the high tuberculosis prevalence in South Africans, due to reduced isoniazid efficacy in the presence of rapid acetylation.
|
12747608 |
2003 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 slow acetylation was observed to increase the risk of AT-DILI in tuberculosis patients.
|
30047605 |
2018 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify polymorphisms of genes encoding metabolic enzymes NAT2 and GSTM1 in tuberculosis patients in Latvia and to estimate the frequency of NAT2 slow acetylator and GSTM1 null genotypes.
|
27236516 |
2016 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
|
29781872 |
2018 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The use of individualized pharmacogenetic-guided INH dosage regimens that incorporate NAT2 genotype and body weight may help to ensure achievement of therapeutic concentrations of INH in the TB patients.
|
26491254 |
2015 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we show the safety and efficacy of a pharmacogenetics-based standard TB therapy and also provide a schematic presentation that proposed therapeutic approaches for latent TB infection (LTBI) using NAT2 genotyping.
|
24798717 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To define the pharmacokinetics of isoniazid (INH) in children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype.
|
15908628 |
2005 |